# RAD001 Plus Bevacizumab in Metastatic Melanoma

> **NCT00591734** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 57 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00591734
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-10
- **Final completion:** 2011-10
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2021-11-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00591734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00591734, "RAD001 Plus Bevacizumab in Metastatic Melanoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00591734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*